Citius receives fda response on pre-ind application for acute respiratory distress syndrome treatment in patients with covid-19

Citius receives fda response on pre-investigational new drug (pind) application for its induced mesenchymal stem cells (imscs) to treat acute respiratory distress syndrome (ards) in patients with covid-19.citius pharmaceuticals inc - intends to submit an ind application for its imsc therapy for patients with ards associated with covid-19.
CTXR Ratings Summary
CTXR Quant Ranking